Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.
Type:
Grant
Filed:
November 26, 2018
Date of Patent:
March 29, 2022
Assignee:
MediBeacon Inc.
Inventors:
Richard B. Dorshow, Steven J. Hanley, Phillip I. Tarr
Abstract: A functional gadolinium contrast agent comprising a gadolinium cation and a ligand secured to the gadolinium cation is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing gadolinium contrast agents from a patient is disclosed, the method comprising providing a gadolinium contrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the gadolinium contrast agent to the patient; conducting a magnetic resonance imaging procedure; and sequestering the gadolinium contrast agent on the capture substrate. A system for removing gadolinium contrast agents is also disclosed.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
January 18, 2022
Assignee:
Boston Scientific Scimed, Inc.
Inventors:
Joseph Thomas Delaney, Jr., Douglas Dean Pagoria, Douglas Pennington, Paul Sorajja
Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly a metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent that can be used not only as a T1 MRI contrast agent but also as a T2 MRI contrast agent, and a method for producing the same. The metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent can provide more accurate and detailed information associated with disease than single MRI contrast agent by the beneficial contrast effects in both T1 imaging with high tissue resolution and T2 imaging with high feasibility on detection of a lesion.
Type:
Grant
Filed:
July 20, 2020
Date of Patent:
January 11, 2022
Assignee:
INTRON BIOTECHNOLOGY, INC.
Inventors:
Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
Abstract: Boron Enriched Linker (“BEL”) compositions and methods of making BELs are disclosed herein. Consequently, the BELs can be conjugated to antibodies or antibody fragments to create Antibody Boron Conjugates (“ABCs”) to provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.
Abstract: An imaging contrast composition comprising an iodinated contrast agent and a ligand secured to the iodinated contrast agent is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing iodinated radiocontrast agents from a patient is disclosed, the method comprising providing an iodinated radiocontrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the iodinated radiocontrast agent to the patient; conducting procedure CT scan or procedure using fluoroscopy; and sequestering the iodinated radiocontrast agent on the capture substrate.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
January 4, 2022
Assignee:
Boston Scientific Scimed, Inc.
Inventors:
Joseph Thomas Delaney, Jr., Douglas Dean Pagoria, Richard Lee Tadsen, Andrew J. Ro, Joel T. Eggert, Douglas Pennington, Paul Sorajja, Sarah Melissa Gruba, Tatyana Dyndikova
Abstract: The invention relates to a process for the preparation of a diagnostic X-ray composition. The composition comprises a non-ionic X-ray contrast agent in a pharmaceutically acceptable carrier. More particularly, the invention relates to a process for secondary production of X-ray compositions comprising X-ray contrast agents with a high dissolution temperature. When using the process of the invention, precipitation is avoided and degradation of the contrast agent is reduced. The process of the invention includes heat treatment of iodinated X-ray contrast agents at low pH.
Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
Type:
Grant
Filed:
November 1, 2019
Date of Patent:
November 23, 2021
Assignee:
Wyeth LLC
Inventors:
Eric Joel Benjamin, Wendy Ann Dulin, Yanning Lin, Kai Zhuang
Abstract: Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein L1 and L2 are each independently a covalent bond or a divalent linking group, R is a detectable label or therapeutic drug and B is an albumin binding moiety. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells using a compound of Formula (I).
Abstract: The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
Abstract: A liposomal composition (“ADx-001”) is provided, ADx-001 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand. The macrocyclic gadolinium-based imaging agent may be conjugated to a fourth phospholipid.
Type:
Grant
Filed:
January 29, 2021
Date of Patent:
September 14, 2021
Assignee:
Texas Children's Hospital
Inventors:
Eric A. Tanifum, Ketankumar B. Ghaghada, Ananth V. Annapragada
Abstract: The present invention relates to in vivo imaging and in particular to magnetic resonance imaging (MRI). Provided by the present invention is a pharmaceutical formulation suitable for use in an MRI procedure and which offers advantages over known such formulations. A particular dose of the pharmaceutical formulation of the invention is also envisioned as well as the use of said dose in a method of in vivo imaging. This present invention provides for simultaneous administration of a liver specific agent and a second MR contrast agent that is capable of better/further enhancing the dynamic vascular phase in a patient. The method of the invention has the advantage of simplicity and patient comfort, compared to sequential injections. Furthermore, the method of the invention provides the advantage that it can enable a lower cumulative dose of contrast agents.
Type:
Grant
Filed:
November 30, 2016
Date of Patent:
September 7, 2021
Assignee:
GE HEALTHCARE AS
Inventors:
Andreas Richard Meijer, Mikkel Jacob Thaning, Paritosh Jayant Dhawale, Salvatore Desena, Paul Alexander Jones, Deirdre Cassidy, Concetta Valeria Gringeri
Abstract: The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
September 7, 2021
Assignee:
GENERAL ELECTRIC COMPANY
Inventors:
Brian Christopher Bales, Michael James Rishel
Abstract: A composition for cross talk between estrogen receptors and cannabinoid receptors including a chelator and a receptor ligand is provided. A method of synthesizing the composition is also provided, and the composition may be further prepared in pharmaceutical formulations or kits for therapy or molecular imaging.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
August 17, 2021
Assignee:
SeeCure Taiwan Co., Ltd.
Inventors:
Tsung-Tien Kuo, David J. Yang, Wei-Chung Chang, Min-Ching Chung, Chi-Shiang Ke
Abstract: Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.
Type:
Grant
Filed:
November 11, 2014
Date of Patent:
August 3, 2021
Assignee:
MediBeacon Inc.
Inventors:
Richard B Dorshow, Steven J. Hanley, Phillip I. Tarr
Abstract: Suspension of gas-filled microvesicles comprising a targeting ligand for binding to KDR or VEGF/KDR complex. The suspension is obtained by reconstituting a freeze-dried residue with a carbohydrate-containing solution in the presence of a physiologically acceptable gas and is stabilized by the presence of histidine.
Abstract: The present invention is directed towards new chemical entities based on a lipid-paramagnetic metal ion chelate. The lipid portion of the compound intercalates into the membrane of a liposome. The compounds of the invention find particular use as paramagnetic contrast media for magnetic resonance imaging. It has been surprisingly discovered that the liposomal contrast media do not substantially cross the placental barrier into the vasculature of the fetus(es) when administered to a pregnant subject. These novel compounds are useful in the diagnosis of disorders and diseases in both gravid and non-gravid subjects. The invention is also directed towards pharmaceutical compositions comprising these compounds and the uses of these compounds.
Type:
Grant
Filed:
September 15, 2017
Date of Patent:
July 6, 2021
Assignee:
TEXAS CHILDREN'S HOSPITAL
Inventors:
Ananth Annapragada, Anil Shetty, Ketankumar B Ghaghada, Eric Tanifum
Abstract: The invention relates to octadentate ligands of a general formula R1-D-X-D-X-D-X-D-E-R2, wherein D is C(O)N(OH) or N(OH)C(O), pyrimidinone or pyridinone, each X independently of any other X is a saturated or partially unsaturated, substituted or unsubstituted linker comprising 8-11 atoms selected from any of N, C, O; R1 is alkyl, cycloalkyl, arene, or heteroarene, E is a saturated or partially unsaturated, substituted or unsubstituted chain comprising 1-50 atoms and R2 is a moiety capable of selectively binding to a biomolecule, or a nanoparticle. The invention further relates to complexes of the ligand, particularly radionuclides and their use in radioimmunotherapy and imaging.
Abstract: The present invention relates to a peptide thiourea derivative, a pharmaceutically acceptable salt thereof, a radioisotope labeled compound comprising the same, and a pharmaceutical composition for treating or diagnosing prostate cancer comprising the same as an active ingredient. The peptide thiourea derivative of the present invention is excellent in stability in human serum when it is administered in vivo and not only binds well to PSMA expressed in prostate cancer but also inhibits excellently PSMA at a low concentration. Besides, the derivative of the invention has a high water-solubility and can be excreted through the kidney not through the bile passage so that a clear image of the tumor region of prostate cancer can be obtained. Therefore, the derivative of the present invention can be effectively used as a pharmaceutical composition for treating and diagnosing prostate cancer.
Type:
Grant
Filed:
November 9, 2016
Date of Patent:
June 8, 2021
Assignee:
Cellbion Co., Ltd
Inventors:
Jae Min Jeong, Sung-Hyun Moon, Yun-Sang Lee
Abstract: The present invention relates to new class of functionalized macrocycles capable of chelating paramagnetic metal ions, their chelated complexes with metal ions and the use thereof as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.
Type:
Grant
Filed:
June 30, 2020
Date of Patent:
June 1, 2021
Assignee:
BRACCO IMAGING S.P.A.
Inventors:
Luciano Lattuada, Roberta Napolitano, Valeria Boi, Massimo Visigalli, Silvio Aime, Giovanni Battista Giovenzana, Alberto Fringuello Mingo